Long-term stable disease in a 70-year-old man with recurrent biopsy-proven thyroid carcinoma metastatic to the lungs enrolled in the previously published feasibility study (Barbault et al, 2009).
We performed a subgroup analysis of 4,361 ED patients enrolled in the previously reported multicenter observational study.
Eleven patients were enrolled in the previously untreated group.
All pregnant women were enrolled in a previously defined area, southeast of Italy, in the Vito Fazzi Hospital, Italy, and Departments of Obstetrics and Gynecology assessed the investigation.
Present retrospective analysis evaluated consecutive young-elderly patients 65 to 75 years enrolled in a previously reported phase II study [ 1] and in the expanded clinical program proposing first-line FIr-B/FOx treatment.
Though asymptomatic and without any metastatic disease to bone, in October 2008, the patient was enrolled in the previously described open-label, phase I II study 12 and was treated with 10 cycles of docetaxel and continuous dasatinib.
The study subjects were adults (≥ 18 years) hospitalized with sepsis, who were enrolled in a previously reported study of microvascular reactivity; more detail of subject recruitment, patient characteristics and study procedures are provided in this paper [ 15].
We included adults who were admitted to a medical ICU for acute hypercapnic respiratory failure, treated with NIV for at least two days and enrolled in two previously published studies [ 7, 20].
A subgroup analysis of subjects enrolled in the previously mentioned trial by Simonneau et al 16 reported outcomes for study subjects with PAH specifically due to underlying connective tissue disease.
Patients were excluded if they had been enrolled in the previously reported development cohort (DC) or retrospective validation cohort (RVC) [ 17], or if research staff could not review their medical records within 48 h of being alerted.
Here, we report a retrospective analysis evaluating activity, efficacy, and safety of first-line FIr-B/FOx intensive regimen and the prognostic value of extension of metastatic disease [ 4, 5] in fit young-elderly MCRC patients enrolled in a previously reported phase II study [ 1] and in the expanded clinical program proposing first-line FIr-B/FOx treatment.
